These authors concluded that their findings highlight a potential role of TAM HIF1α in ccRCC progression and support the reevaluation of HIF1α as a therapeutic target and marker of disease progression [74]. This evidence concerns the gene HIF1A and nonpapillary renal cell carcinoma.